Aminophylline 3%, Co-dergocrine Mesylate 0.05%, and Isosorbide Dinitrate 0.25% Cream for the Treatment of Orgasmic Dysfunction in Women

A subscription to IJPC includes a print copy delivered by postal mail and on-line access to electronic PDF copies of your subscribed issues.

LEARN MORE

Aminophylline 3%, Co-dergocrine Mesylate 0.05%, and Isosorbide Dinitrate 0.25% Cream for the Treatment of Orgasmic Dysfunction in Women

Author(s): Mason Dave

Issue: Jul/Aug 2002 - Compounding for BHRT and Legal and Regulatory Issues
View All Articles in Issue

Page(s): 255-256

Aminophylline 3%, Co-dergocrine Mesylate 0.05%, and Isosorbide Dinitrate 0.25% Cream for the Treatment of Orgasmic Dysfunction in Women Page 1

Aminophylline 3%, Co-dergocrine Mesylate 0.05%, and Isosorbide Dinitrate 0.25% Cream for the Treatment of Orgasmic Dysfunction in Women Page 2

Download in electronic PDF format for $65

Abstract: A formulation for preparing Aminophylline 3%, Co-dergocrine Mesylate 0.05%, and Isosorbide Dinitrate 0.25% Cream for the Treatment of Orgasmic Dysfunction in Women. Includes ingredients, method of preparation, discussion, and references for the compounding pharmacist.

Related Keywords: Aminophylline 3%, co-dergocrine mesylate 0.05%, and isosorbide dinitrate 0.25% cream, for orgasmic dysfunction in women, Co-dergocrine mesylate 0.05%, aminophylline 3%, and isosorbide dinitrate 0.25% cream, for orgasmic dysfunction in women, Isosorbide dinitrate 0.25%, aminophylline 3%, and co-dergocrine mesylate 0.05% cream, for orgasmic dysfunction in women, Orgasmic dysfunction in women, treatment of, libido

Related Categories: FORMULATIONS, HRT, MENTAL HEALTH

Printer-Friendly Version

Title/Author (Click for Abstract / Details / Purchase)	Issue/Page View/Buy
Related Articles from IJPC
Aminophylline 3%, Co-dergocrine Mesylate 0.05%, and Isosorbide Dinitrate 0.25% Cream for the Treatment of Orgasmic Dysfunction in Women Mason Dave	Jul/Aug 2002 Pg. 255-256
Androgen Deficiency in Women: Understanding the Science, Controversy and Art of Treating Our Patients - Part 1 Cutter Christopher B	Jan/Feb 2004 Pg. 16-21
A Perspective on HRT for Women: Picking Up the Pieces After the Women's Health Initiative Trial - Part 2 Gillson George R, Zava David T	Sep/Oct 2003 Pg. 330-338
Isosorbide Dinitrate 0.1% Topical Spray Allen Loyd V Jr	Mar/Apr 2005 Pg. 152
Long-term Physicochemical Stability of Concentrated Solutions of Isosorbide Dinitrate in Polypropylene Syringes for Administration in the Intensive Care Unit Lardinois Benjamin, Dimitriou Alexandre, Delcave Charlotte, Soumoy Laura, Jamart Jacques, Bihin Benoît, Hecq Jean-Daniel, Galanti Laurence M	Jan/Feb 2020 Pg. 64-68
Women's Oral Health: Is There a Hormonal Link? Preckshot John	Jan/Feb 2004 Pg. 10-14
Androgen Deficiency in Women: Understanding the Science, Controversy and Art of Treating Our Patients - Part 2 Cutter Christopher B	Mar/Apr 2004 Pg. 96-99
Estradiol 0.25 mg/g, Estrone 0.25 mg/g, and Estriol 2 mg/g in HRT Cream Base Allen Loyd V Jr	Sep/Oct 2016 Pg. 407
Estriol 2-mg/mL, Estrone 0.25-mg/mL, and Estradiol 0.25-mg/mL Topical Solution Allen Loyd V Jr	Jul/Aug 2002 Pg. 298
Reversing Erectile Dysfunction and Urinary Incontinence After Prostatectomy or Radiotherapy: The Stanley Prostate-Cancer Treatment Protocol McKettrick Greg, Yoch Doug	Jan/Feb 2021 Pg. 18-23

Particle Measuring Systems - USP <797> Environmental Monitoring Solutions